L3VLUP

NBIX in the 13F filings

Neurocrine Biosciences Inc · CUSIP 64125C109

Q3 2026: 5 of 95 managers have filed so far; the filing deadline is 16 November 2026. Its figures cover those filers only, so it is not yet a picture of the tracked managers.

Quarter end
30 Sep 2026
the date the book describes
Filed
9 Nov 2026
latest of these filings; the earliest 9 Nov 2026
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
5
filed both Q2 2026 and Q3 2026; 1 listed it in both
Shares listed
420,296
combined, among listed positions
Reported value
$60m
combined, at the quarter end

Among the 5 comparable managers: 0 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -65,218.

Managers listing NBIX in Q3 2026

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2026, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Acadian Asset Management LLC388,612$55m0.06%Trimmed-52,7599 Nov 2026 (the filing on sec.gov)
Squarepoint Ops LLC31,684$4.5munder 0.1%Trimmed-12,4599 Nov 2026 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2026 to Q3 2026, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
14 in Q4 2024 to 1 in Q3 2026

Tracked managers listing it, at least.

01020302014201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
NBIX by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20131$2.7mn.a.n.a.
Q3 20131$5.9mn.a.n.a.
Q4 20131$4.9mn.a.n.a.
Q1 20142$184mn.a.n.a.
Q2 20142$19mn.a.n.a.
Q3 20142$174mn.a.n.a.
Q4 20143$278mn.a.n.a.
Q1 20155$990mn.a.n.a.
Q2 20157$1.1bnn.a.n.a.
Q3 20157$975mn.a.n.a.
Q4 20158$1.6bnn.a.n.a.
Q1 20166$1.1bnn.a.n.a.
Q2 20169$1.2bnn.a.n.a.
Q3 201611$1.5bnn.a.n.a.
Q4 20167$959mn.a.n.a.
Q1 20177$960mn.a.n.a.
Q2 201711$1.5bnn.a.n.a.
Q3 201713$2.2bnn.a.n.a.
Q4 201717$2.8bnn.a.n.a.
Q1 201813$3.0bnn.a.n.a.
Q2 201815$3.6bnn.a.n.a.
Q3 201820$4.3bnn.a.n.a.
Q4 201816$2.4bnn.a.n.a.
Q1 201918$2.6bnn.a.n.a.
Q2 201912$2.2bnn.a.n.a.
Q3 201912$2.4bnn.a.n.a.
Q4 201919$2.8bnn.a.n.a.
Q1 202013$2.2bnn.a.n.a.
Q2 202012$3.3bnn.a.n.a.
Q3 202015$2.6bnn.a.n.a.
Q4 202012$2.6bnn.a.n.a.
Q1 20216$2.3bnn.a.n.a.
Q2 20219$1.5bnn.a.n.a.
Q3 20218$1.5bnn.a.n.a.
Q4 202114$1.3bnn.a.n.a.
Q1 202215$1.4bnn.a.n.a.
Q2 202211$1.3bnn.a.n.a.
Q3 202214$1.0bnn.a.n.a.
Q4 202215$1.2bnn.a.n.a.
Q1 202317$860mn.a.n.a.
Q2 202316$1.1bnn.a.n.a.
Q3 202324$1.4bnn.a.n.a.
Q4 202321$1.6bn1012
Q1 202419$1.5bn911
Q2 202417$1.4bn109
Q3 202411$1.2bn75
Q4 202414$2.0bn104
Q1 202514$1.6bn104
Q2 202516$2.5bn107
Q3 202515$2.6bn78
Q4 202521$2.8bn1721
Q1 202617$2.9bn1619
Q2 202610$2.7bn1616
Q3 20261$55m02

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

NBIX and GILD →NBIX and AMGN →NBIX and ARGX →Choose a stock to compare with NBIX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own NBIX, latest filings →Back to the 13F Explorer →